Glucagon-Like Peptide 1
FDA Confirms Tirzepatide Availability, Compounders Express Concerns, While Semaglutide Shortage Persists
FDA, tirzepatide, semaglutide, GLP-1 drug shortage, compounders, pharmaceutical availability
Novo Nordisk’s Vision for the Future of GLP-1 Therapies: Expanding Beyond Diabetes and Obesity
GLP-1 agonists, Novo Nordisk, Type 2 diabetes, Obesity, Future treatments, Chronic diseases, Semaglutide, Tirzepatide, Therapeutic advancements
Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug
Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits
Healthcare Evolution 2025: AI, IRA, and GLP-1s Redefine the Industry
AI in Healthcare, IRA Impact on Biopharma, GLP-1 Medications, Healthcare Trends 2025, Value-Based Care, Telemedicine Integration, Pharmaceutical Industry Shifts, Healthcare Technology Advancements
Metsera Secures $215M to Accelerate Obesity Drug Development
Metsera, Obesity Drug, Funding, Biotech, GLP-1, Metabolic Disease
Metsera Secures $215 Million Series B Funding Following Promising Phase 1 Weight Loss Data
Metsera, Series B funding, weight loss, obesity treatment, GLP-1 drugs, NuSH peptides
UK Health Secretary Warns Against Misuse of GLP-1 Weight Loss Drugs for Aesthetic Purposes
GLP-1 agonists, weight loss drugs, misuse, aesthetic weight loss, UK health secretary, MHRA warnings
Novo Nordisk Secures $285 Million Biobucks Deal with Ascendis Pharma for Monthly GLP-1 Agonist Development
Novo Nordisk, Ascendis Pharma, GLP-1 agonist, biobucks deal, pharmaceutical development
Novo Nordisk Seeks FDA Ban on Compounded Semaglutide Formulations Amid Safety Concerns
Novo Nordisk, FDA, semaglutide, compounding pharmacies, safety concerns, GLP-1 medications, weight loss drugs, diabetes treatments
Noom and Waltz Health Collaborate on Affordable GLP-1 Weight Loss Program
Noom, Waltz Health, GLP-1, weight loss, affordable, medication management, obesity treatment